PE20031052A1 - Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la cicloxigenasa-2 - Google Patents

Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la cicloxigenasa-2

Info

Publication number
PE20031052A1
PE20031052A1 PE2003000166A PE2003000166A PE20031052A1 PE 20031052 A1 PE20031052 A1 PE 20031052A1 PE 2003000166 A PE2003000166 A PE 2003000166A PE 2003000166 A PE2003000166 A PE 2003000166A PE 20031052 A1 PE20031052 A1 PE 20031052A1
Authority
PE
Peru
Prior art keywords
alpha
cycloxygenase
combinations
selective inhibitor
delta ligand
Prior art date
Application number
PE2003000166A
Other languages
English (en)
Inventor
Taylor
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20031052A1 publication Critical patent/PE20031052A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

SE REFIERE A UNA COMPOSICION QUE COMPRENDE: a) VALDECOXIB O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES Y b) UN LIGANDO ALFA-2-DELTA SELECCIONADO DE GABAPENTINA, PREGABALINA, HIDROCLORURO DE 3-(1-AMINOMETIL-CICLOHEXILMETIL)-4H-[1,2,4]-OXADIAZOL-5-ONA, (3S,4S)-(1-AMINOMETIL-3,4-DIMETIL-CICLOPENTIL)-ACETICO. LA COMPOSICION COMPRENDE ADEMAS UN VEHICULO, DILUYENTE FARMACEUTICAMENTE ACEPTABLE Y ES UTIL PARA EL TRATAMIENTO DE INFLAMACION, OSTEOARTRITIS, ARTRITIS REUMATOIDE
PE2003000166A 2002-02-22 2003-02-17 Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la cicloxigenasa-2 PE20031052A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35929502P 2002-02-22 2002-02-22
US40436502P 2002-08-19 2002-08-19

Publications (1)

Publication Number Publication Date
PE20031052A1 true PE20031052A1 (es) 2003-12-24

Family

ID=27760521

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000166A PE20031052A1 (es) 2002-02-22 2003-02-17 Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la cicloxigenasa-2

Country Status (21)

Country Link
US (1) US20030199567A1 (es)
EP (1) EP1480639A1 (es)
JP (1) JP2005523281A (es)
KR (1) KR20040085216A (es)
CN (1) CN1635887A (es)
AR (1) AR038531A1 (es)
AU (1) AU2003246864A1 (es)
BR (1) BR0307906A (es)
CA (1) CA2476438A1 (es)
CO (1) CO5611109A2 (es)
HN (1) HN2003000071A (es)
IL (1) IL162932A0 (es)
MX (1) MXPA04008175A (es)
NO (1) NO20043947L (es)
PA (1) PA8567201A1 (es)
PE (1) PE20031052A1 (es)
PL (1) PL372210A1 (es)
RU (1) RU2286151C2 (es)
TW (1) TW200303214A (es)
UY (1) UY27675A1 (es)
WO (1) WO2003070237A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2509605C (en) * 2002-12-13 2010-10-05 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
ES2275229T3 (es) * 2003-03-21 2007-06-01 Dynogen Pharmaceuticals, Inc. Metodos para el tratamiento de desordenes del tracto urinario iferior utilizando antimuscarinos y moduladores de la subunidad alfa-2-delta del canal de calcio.
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
ATE449633T1 (de) * 2003-09-12 2009-12-15 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
EP1682149B1 (en) * 2003-10-23 2009-12-02 Medtronic, Inc. Injectable gabapentin compositions
JP2009533368A (ja) * 2006-04-11 2009-09-17 ノバルティス アクチエンゲゼルシャフト 有機化合物
JP2010513357A (ja) * 2006-12-22 2010-04-30 ノバルティス アーゲー Dpp−iv阻害剤としての1−アミノメチル−1−フェニル−シクロヘキサン誘導体
US20090275529A1 (en) * 2008-05-05 2009-11-05 Reiss Allison B Method for improving cardiovascular risk profile of cox inhibitors
KR101641519B1 (ko) * 2008-09-05 2016-07-21 그뤼넨탈 게엠베하 3-(3-디메틸아미노-1-에틸-2-메틸-프로필)-페놀과 항간질제의 약제학적 병용물
KR102631399B1 (ko) 2018-03-30 2024-02-01 씨지인바이츠 주식회사 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물
WO2022093978A1 (en) * 2020-10-28 2022-05-05 Tremeau Pharmaceuticals, Inc. Aqueous formulations of water insoluble cox-2 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234929A (en) * 1992-07-20 1993-08-10 William Chelen Method of treating motion sickness with anticonvulsants and antitussive agents
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5420270A (en) * 1993-10-07 1995-05-30 G. D. Searle & Co. Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5352638A (en) * 1994-02-22 1994-10-04 Corning Incorporated Nickel aluminosilicate glass-ceramics
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
EP1011658B1 (en) * 1997-09-08 2005-12-07 Warner-Lambert Company Llc Analgesic compositions comprising anti-epileptic compounds and methods of using same
PL341231A1 (en) * 1997-12-16 2001-03-26 Warner Lambert Co 4(3)-substitute derivatives of 4(3)aminomethyl(thio)pyrane or piperidine derivatives (analogues of garbapentin), their production and application in treating neurological disorders
WO2000053225A1 (en) * 1999-03-10 2000-09-14 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB9927844D0 (en) * 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
CN1679556A (zh) * 1999-12-08 2005-10-12 法马西亚公司 维得克西组合物

Also Published As

Publication number Publication date
TW200303214A (en) 2003-09-01
WO2003070237A1 (en) 2003-08-28
CN1635887A (zh) 2005-07-06
BR0307906A (pt) 2004-12-21
NO20043947L (no) 2004-09-21
UY27675A1 (es) 2003-09-30
EP1480639A1 (en) 2004-12-01
HN2003000071A (es) 2003-11-24
CA2476438A1 (en) 2003-08-28
AU2003246864A1 (en) 2003-09-09
AR038531A1 (es) 2005-01-19
KR20040085216A (ko) 2004-10-07
CO5611109A2 (es) 2006-02-28
PA8567201A1 (es) 2003-11-12
IL162932A0 (en) 2005-11-20
MXPA04008175A (es) 2004-11-26
RU2286151C2 (ru) 2006-10-27
JP2005523281A (ja) 2005-08-04
US20030199567A1 (en) 2003-10-23
RU2004125609A (ru) 2006-01-27
PL372210A1 (en) 2005-07-11

Similar Documents

Publication Publication Date Title
PE20031052A1 (es) Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la cicloxigenasa-2
PE20040760A1 (es) C-aril-glucosidos como inhibidores de sglt2
BRPI0413363A (pt) formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
HN2001000010A (es) Sintesis asimetrica de pregabalin
UY27639A1 (es) Composiciones farmacéuticas de inhibidores de la proteína de transferencia de ésteres de colesterilo
BR9812133A (pt) Análogos de gaba para prevenir e tratar danos gastrintestinais
ATE303178T1 (de) Acc-hemmer
BRPI0406531A (pt) extensões de mensagem de descrição de sessão
ATE286060T1 (de) Präpolymere (meth)acrylate mit polycyclischen oder aromatischen segmenten
ATE283051T1 (de) Synergistisch,analgetische zusammensetzung mit opiod-analgetika und zyklooxygenase-2 inhibitoren
PA8523901A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester
ATE374917T1 (de) Zerlegbares gewehr
PE20040992A1 (es) Combinaciones sinergicas entre un ligando alfa-2-delta y un inhibidor de pdev
CY1105429T1 (el) Φαρμακευτικη συνθεση συνδυαζουσα τενατοπραζολη και ενα αντιφλεγμονωδες
BR0318170A (pt) unidade divisora de uma tubuladura de válvula de estrangulamento
SE0001162D0 (sv) Projektil
WO2004065844A3 (en) Method and apparatus for charging efflorescent material utilizing ultra violet light
FR2897864B1 (fr) Composition d'amorcage et applications
FR2848116B1 (fr) Composition cosmetique comprenant un inhibiteur des metallo-proteinases et un lipopeptide.
BR0317115A (pt) Processo contìnuo para produzir um material orgânico tendo uma arquitetura visada
BRPI0510634A (pt) tubo ascendente marìtimo compósito
DK1100793T3 (da) Krystalmodifikation af liponsyre
AU2003281169A1 (en) Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
DE502007006403D1 (de) Wirkstoff-stabilisierende o/w-emulsionen ii
WO2003057205A3 (de) KOMBINATION VON MTP INHIBITOREN ODER apoB-SEKRETIONS-INHIBITOREN MIT FIBRATEN ZUR VERWENDUNG ALS ARZNEIMITTEL

Legal Events

Date Code Title Description
FC Refusal